FDA Clears First Oral GLP-1 for Weight Loss On December 22, 2025, the FDA approved Novo Nordisks once-daily Wegovy pill (25 mg semaglutide), the first oral GLP-1 receptor agonist indicated for chronic weight management and cardiovascular risk reduction in adults with obesity or overweight plus at least one weight-related comorbidity
Stimple SD, Kalyoncu S, Desai AA, Mogensen JE, Spang LT, Asgreen DJ, et al
To prevent and treat cancer Small studies suggest this supplement might prevent certain pre-cancerous damage, but there is no proof that it can prevent cancer
Marx N, Burgmaier M, Heinz P, Ostertag M, Hausauer A, Bach H, et al
It is also important to remember that poorly controlled diabetes and obesity themselves increase the risk of gum disease, infections and delayed healing